Clinical Trial

IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

Name: IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer — clinical trial record (NCT07408635)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is a single-arm, phase II clinical trial evaluating the safety and efficacy of IBI363 combined with chemotherapy as a neoadjuvant treatment of non-small cell lung cancer.

Trial Details

NCT Number	NCT07408635
Lead Sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Conditions	Unresectable Stage III Non-small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
Enrollment	43 participants
Start Date	2026-01-07
Primary Completion	2028-06-06 (estimated)
Study Completion	2030-01-06 (estimated)
Updated on ClinicalTrials.gov	2026-02-13